Your browser is no longer supported. Please, upgrade your browser.
ALBO [NASD]
Albireo Pharma, Inc.
Index- P/E- EPS (ttm)-6.86 Insider Own0.90% Shs Outstand19.11M Perf Week-6.39%
Market Cap582.06M Forward P/E- EPS next Y-4.51 Insider Trans-16.75% Shs Float16.06M Perf Month-9.85%
Income-107.60M PEG- EPS next Q-1.77 Inst Own94.60% Short Float11.59% Perf Quarter-28.96%
Sales8.30M P/S70.13 EPS this Y-33.50% Inst Trans0.19% Short Ratio10.85 Perf Half Y-6.88%
Book/sh9.49 P/B3.18 EPS next Y36.80% ROA-44.70% Target Price- Perf Year21.44%
Cash/sh13.03 P/C2.32 EPS next 5Y- ROE-72.30% 52W Range22.08 - 49.00 Perf YTD-19.51%
Dividend- P/FCF- EPS past 5Y-0.90% ROI- 52W High-38.39% Beta1.54
Dividend %- Quick Ratio10.40 Sales past 5Y- Gross Margin- 52W Low36.73% ATR1.47
Employees90 Current Ratio10.40 Sales Q/Q-57.80% Oper. Margin- RSI (14)36.45 Volatility5.09% 4.56%
OptionableYes Debt/Eq0.05 EPS Q/Q-119.20% Profit Margin- Rel Volume1.16 Prev Close30.40
ShortableYes LT Debt/Eq0.05 EarningsMay 06 BMO Payout- Avg Volume171.39K Price30.19
Recom1.50 SMA20-5.79% SMA50-11.15% SMA200-12.43% Volume198,702 Change-0.69%
Dec-18-20Reiterated H.C. Wainwright Buy $67 → $75
Aug-19-20Reiterated H.C. Wainwright Buy $64 → $50
Jul-31-20Initiated Piper Sandler Overweight $45
Jun-25-20Initiated Robert W. Baird Outperform $52
Feb-28-19Initiated H.C. Wainwright Buy $62
Apr-20-18Initiated Jefferies Buy $50
Nov-15-17Initiated ROTH Capital Buy $92
Jul-18-17Initiated Needham Buy $35
Jun-30-17Initiated Wedbush Outperform $58
Feb-16-17Initiated Ladenburg Thalmann Buy $40
May-06-21 09:45AM  
08:30AM  
Apr-29-21 08:30AM  
Apr-13-21 08:30AM  
Apr-06-21 08:30AM  
Mar-25-21 08:30AM  
Feb-27-21 01:09AM  
Feb-26-21 08:30AM  
12:31AM  
Feb-25-21 08:00AM  
Feb-23-21 08:30AM  
Feb-18-21 08:30AM  
Feb-17-21 04:30PM  
Feb-11-21 08:30AM  
Feb-05-21 12:03AM  
Jan-25-21 08:00AM  
Jan-22-21 08:30AM  
Jan-14-21 04:30PM  
Jan-07-21 08:30AM  
Jan-06-21 04:30PM  
Jan-05-21 08:30AM  
Dec-29-20 09:25AM  
Dec-24-20 09:54AM  
Dec-19-20 06:11PM  
Dec-17-20 08:00AM  
Dec-11-20 04:30PM  
Dec-08-20 04:30PM  
Nov-30-20 09:02AM  
Nov-20-20 10:45AM  
Nov-13-20 08:05AM  
Nov-12-20 08:00AM  
Nov-07-20 07:21AM  
Nov-05-20 07:30AM  
Nov-02-20 08:00AM  
Oct-23-20 09:20AM  
Oct-20-20 09:03AM  
Oct-05-20 08:30AM  
Oct-02-20 04:30PM  
Sep-19-20 07:00AM  
Sep-15-20 11:28AM  
Sep-09-20 09:16PM  
10:19AM  
10:08AM  
07:23AM  
Sep-08-20 04:01PM  
12:34PM  
06:30AM  
Sep-07-20 04:36PM  
Sep-03-20 08:47AM  
Aug-27-20 08:04AM  
Aug-21-20 09:00AM  
Aug-19-20 10:17AM  
Aug-18-20 04:40PM  
Aug-06-20 07:30AM  
Jul-30-20 04:01PM  
08:00AM  
Jul-27-20 11:42PM  
Jul-20-20 08:00AM  
Jul-14-20 07:30AM  
Jul-13-20 09:57AM  
Jul-10-20 08:40AM  
Jul-05-20 11:02PM  
Jul-01-20 10:23AM  
Jun-10-20 08:00AM  
Jun-09-20 07:30AM  
May-26-20 08:00AM  
May-12-20 06:29AM  
May-11-20 06:25AM  
May-08-20 03:30AM  
May-07-20 07:45AM  
07:30AM  
May-03-20 08:34AM  
Apr-30-20 09:47AM  
Apr-07-20 08:30AM  
Mar-10-20 08:30AM  
Mar-04-20 05:05AM  
Mar-02-20 07:30AM  
Feb-29-20 02:52PM  
Feb-27-20 09:12AM  
08:00AM  
Feb-26-20 08:30AM  
Feb-24-20 08:30AM  
Feb-03-20 04:01PM  
Jan-29-20 09:57PM  
04:06PM  
04:01PM  
Jan-23-20 08:00AM  
Dec-19-19 09:51PM  
09:17AM  
Dec-17-19 05:06AM  
Nov-14-19 08:30AM  
Nov-06-19 02:51PM  
07:30AM  
Nov-04-19 08:30AM  
Nov-02-19 09:26AM  
Nov-01-19 08:30PM  
Oct-30-19 08:00AM  
Oct-03-19 08:00AM  
Sep-30-19 09:23AM  
Sep-18-19 06:05AM  
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duncan JasonChief Legal Officer and GCApr 23Sale32.322227,1757,849Apr 26 06:13 PM
Duncan JasonChief Legal Officer and GCApr 22Sale31.75902,8588,071Apr 26 06:13 PM
Horn Patrick TaylorChief Medical OfficerApr 22Sale31.75902,85811,893Apr 26 06:10 PM
Harford Simon N.R.CFO and TreasurerApr 12Sale32.12922,95512,196Apr 14 04:31 PM
Duncan JasonChief Legal Officer and GCApr 01Option Exercise24.043007,2128,461Apr 02 08:55 PM
Duncan JasonChief Legal Officer and GCApr 01Sale36.1630010,8478,161Apr 02 08:55 PM
Duncan JasonChief Legal Officer and GCMar 31Sale35.041,42649,9698,161Apr 02 08:55 PM
Stephenson PamelaChief Commercial OfficerMar 29Sale34.0242214,35526,985Mar 31 07:21 PM
Mattsson JanChief Scientific OfficerMar 03Sale36.2040014,48137,574Mar 03 06:45 PM
Mattsson JanChief Scientific OfficerMar 02Sale36.2815,770572,20737,974Mar 03 06:45 PM
Mattsson JanChief Scientific OfficerMar 01Option Exercise1.0039,33039,33069,044Mar 03 06:45 PM
Mattsson JanChief Scientific OfficerMar 01Sale37.4515,300572,99653,744Mar 03 06:45 PM
Duncan JasonChief Legal Officer and GCJan 22Sale34.621103,8089,332Jan 25 05:44 PM
Horn Patrick TaylorChief Medical OfficerJan 22Sale34.621103,8089,825Jan 25 05:37 PM
Harford Simon N.R.CFO and TreasurerJan 11Sale37.331104,1074,614Jan 13 04:15 PM
Stephenson PamelaChief Commercial OfficerDec 28Sale39.0746017,97421,907Dec 29 04:19 PM
Horn Patrick TaylorChief Medical OfficerOct 22Sale34.55893,0754,285Oct 23 04:21 PM
Duncan JasonChief Legal Officer and GCOct 22Sale34.71893,0893,781Oct 23 04:19 PM
Harford Simon N.R.CFO and TreasurerOct 12Sale37.30903,3574,616Oct 13 04:06 PM
Stephenson PamelaChief Commercial OfficerSep 25Sale33.2045114,97322,367Sep 25 05:05 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 14Buy40.00400,00016,000,0002,360,139Sep 15 08:30 AM
Carter Martha J.Chief Regulatory OfficerSep 11Option Exercise24.9810,000249,75310,000Sep 15 04:18 PM
Carter Martha J.Chief Regulatory OfficerSep 11Sale40.0310,000400,3000Sep 15 04:18 PM
Carter Martha J.Chief Regulatory OfficerSep 10Option Exercise24.0710,000240,70310,000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 10Sale42.4110,000424,1000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 09Option Exercise20.4010,000204,02510,000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 09Sale38.9710,000389,6500Sep 10 09:02 PM
Duncan JasonChief Legal Officer and GCSep 08Option Exercise24.043,50084,1407,870Sep 10 08:54 PM
Carter Martha J.Chief Regulatory OfficerSep 08Option Exercise19.1910,000191,90010,000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 08Sale45.5510,000455,5000Sep 10 09:02 PM
Duncan JasonChief Legal Officer and GCSep 08Sale45.554,000182,2003,870Sep 10 08:54 PM
Mattsson JanChief Scientific OfficerSep 08Sale45.5510,000455,50024,214Sep 10 08:49 PM
Duncan JasonChief Legal Officer and GCJul 22Sale25.80912,3484,370Jul 23 04:23 PM
Horn Patrick TaylorChief Medical OfficerJul 22Sale25.80912,3484,374Jul 23 04:15 PM
Harford Simon N.R.CFO and TreasurerJul 10Sale25.56922,3524,706Jul 10 05:50 PM
Stephenson PamelaChief Commercial OfficerJun 25Sale30.7939712,22422,818Jun 26 05:02 PM